{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:32:32Z","timestamp":1789824752483,"version":"4.0.1"},"reference-count":39,"publisher":"Termedia Sp. z.o.o.","issue":"3","license":[{"start":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T00:00:00Z","timestamp":1477353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T00:00:00Z","timestamp":1477353600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T00:00:00Z","timestamp":1477353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cent Eur J Immunol"],"abstract":"<jats:p>Systemic lupus erythematosus (SLE) in children is usually more severe than it is in adults and there is a higher incidence of renal involvement. We described 18 children (16 girls, 2 boys) with lupus nephritis (LN), whose average age was 14.4 \u00b11.81 years. Disease activity was assessed according to SLEDAI (SLE Disease Activity Index). Renal biopsy was classified according to the INS\/RPS (International Society of Nephrology\/Renal Pathology Society). The patients were treated with steroids (100%) and pulses of cyclophosphamide (88.9%) or mycophenolate mofetil (11.1%), next azathioprine or mycophenolate mofetil with prednisone in reduced doses. In children with renal\/multi-organ insufficiency and\/or septicaemia, renal replacement therapy (27.8%), and plasmapheresis (22.2%) were used in the initial treatment. The SLEDAI initial activity was high in 44.4% and moderate in 55.6% of children. LN manifested as: nephrotic syndrome (83.3%), microhaematuria (100%), leukocyturia (60%), hypertension (72.2%), and acute renal injury (83.3%); mean GFR was 54.55 \u00b133.09 ml\/min\/1.73 m&lt;sup&gt;2&lt;\/sup&gt;. In the renal biopsy, class IV LN according to INS\/RPS was mainly diagnosed (82%). At the end of follow-up, mean observation time 32.1\u00b123.36 months: mean GFR was 90.87 \u00b112.13 ml\/min\/1.73 m&lt;sup&gt;2&lt;\/sup&gt;, proteinuria disappeared in 66.7% and decreased in 33.3% of children to the average of 1.7 g\/day (range: 0.5-4.0 g\/day), hypertension was observed in 83.4% of children. Intensive immunosuppressive treatment with pulses of cyclophosphamide in early stage of LN in children is very effective.<\/jats:p>","DOI":"10.5114\/ceji.2016.63123","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T06:01:34Z","timestamp":1477634494000},"page":"248-254","source":"Crossref","is-referenced-by-count":15,"title":["Lupus nephritis in children \u2013 10 years\u2019 experience"],"prefix":"10.5114","volume":"41","author":[{"given":"Hanna","family":"Szymanik-Grzelak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Ku\u017ama-Mroczkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga","family":"Ma\u0142dyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Pa\u0144czyk-Tomaszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2016,10,25]]},"reference":[{"key":"ref-1555804","doi-asserted-by":"crossref","unstructured":"Schwartz N, Goilav B (2014): The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol 26: 502-509.","DOI":"10.1097\/BOR.0000000000000089"},{"key":"ref-1555805","doi-asserted-by":"crossref","unstructured":"Lech M, Anders HJ (2013): The pathogenesis of lupus nephritis. J Am Soc Nephrol 24: 1357-1366.","DOI":"10.1681\/ASN.2013010026"},{"key":"ref-1555806","doi-asserted-by":"crossref","unstructured":"Hahn BH, McMahon MA, Wilkinson A, et al. (2012): American College of Rheumatology guidelines for screening, case definition, treatment, and management of lupus nephritis. Arthritis Care Res 64: 797-808.","DOI":"10.1002\/acr.21664"},{"key":"ref-1555807","doi-asserted-by":"crossref","unstructured":"Isenberg D, Appel GB, Contreras G, et al. (2010): Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 49: 128-140.","DOI":"10.1093\/rheumatology\/kep346"},{"key":"ref-1555808","doi-asserted-by":"crossref","unstructured":"Malattia C, Martini A (2013): Paediatric-onset systemic lupus erythematosus. Best Pract Res Clin Rheumatol 27: 351-362.","DOI":"10.1016\/j.berh.2013.07.007"},{"key":"ref-1555809","doi-asserted-by":"crossref","unstructured":"Mina R, Brunner HI (2013): Update on differences between childhood-onset and adult-onset systemic lupus erythematosus 2013. Arthritis Res Therapy 15: 218.","DOI":"10.1186\/ar4256"},{"key":"ref-1555810","doi-asserted-by":"crossref","unstructured":"Feng X, Zou Y, Pan W, et al. (2014): Associations of clinical features and prognosis with age at disease onset in patients with systemic lupus erythematosus. Lupus 23: 327-334.","DOI":"10.1177\/0961203313513508"},{"key":"ref-1555811","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket488"},{"key":"ref-1555812","doi-asserted-by":"crossref","unstructured":"Hiraki LT, Benseler SM, Tyrrell PN, et al. (2008): Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 152: 550-556.","DOI":"10.1016\/j.jpeds.2007.09.019"},{"key":"ref-1555813","doi-asserted-by":"crossref","unstructured":"Wierzbowska M, Gietka P, Rutkowska-Sak L (2014): P\u00f3\u017ane nast\u0119pstwa tocznia rumieniowatego uk\u0142adowego u dzieci. Reumatologia 52: 224-230.","DOI":"10.5114\/reum.2014.44701"},{"key":"ref-1555814","doi-asserted-by":"crossref","unstructured":"Petri M, Orbai AM, Alarc\u00f3n GS, et al. (2012): Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64: 2677-2686.","DOI":"10.1002\/art.34473"},{"key":"ref-1555815","unstructured":"Sag E, Tartaglione A, Batu ED, et al. (2014): Performance of the new SLICC classification criteria in childhood systemic lupus erythematosus: A multicentre study. Clin Exp Rheumatol 32: 440-444."},{"key":"ref-1555816","doi-asserted-by":"crossref","unstructured":"Bombardier C, Gladman DD, Urowitz MM, et al. (1992): Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 35: 630-640.","DOI":"10.1002\/art.1780350606"},{"key":"ref-1555817","doi-asserted-by":"crossref","unstructured":"Gladman D, Ginzler E, Goldsmith C, et al. (1996): The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39: 363-369.","DOI":"10.1002\/art.1780390303"},{"key":"ref-1555818","doi-asserted-by":"crossref","unstructured":"Livingston B, Bonner A, Pope J (2012): Differences in autoantibody profiles and disease activity and damage scores between childhood \u2013 and adult-onset systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 42: 271-280.","DOI":"10.1016\/j.semarthrit.2012.05.001"},{"key":"ref-1555819","doi-asserted-by":"crossref","unstructured":"Weening J, D\u2019AgatiV, Schwartz M, et al. (2004): The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65: 521-530.","DOI":"10.1111\/j.1523-1755.2004.00443.x"},{"key":"ref-1555820","unstructured":"Lupus nephritis. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012; Suppl 2: 221-232."},{"key":"ref-1555821","doi-asserted-by":"crossref","unstructured":"Bertsias GK, Tektonidou M, Amoura Z, et al. (2012): Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71: 1771-1782.","DOI":"10.1136\/annrheumdis-2012-201940"},{"key":"ref-1555822","doi-asserted-by":"crossref","unstructured":"van Vollenhoven RF, Mosca M, Bertsias G, et al. (2014): Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73: 958-967.","DOI":"10.1136\/annrheumdis-2013-205139"},{"key":"ref-1555823","doi-asserted-by":"crossref","unstructured":"Henderson LK, Masson P, Craig JC, et al. (2013): Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 61: 74-87.","DOI":"10.1053\/j.ajkd.2012.08.041"},{"key":"ref-1555824","doi-asserted-by":"crossref","unstructured":"Tian SY, Feldman BM, Beyene J, et al. (2014): Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. J Rheumatol 4: 1998-2007.","DOI":"10.3899\/jrheum.140050"},{"key":"ref-1555825","doi-asserted-by":"crossref","unstructured":"Cimaz R (2012): Pediatric rheumatic disease: Treating lupus nephritis in children \u2013 Is there a gold standard? Nat Rev Rheumatol 8: 192-193.","DOI":"10.1038\/nrrheum.2012.19"},{"key":"ref-1555826","doi-asserted-by":"crossref","unstructured":"Boumpas DT, Austin HA 3rd, Vaughn EM, et al. (1992): Controlled trial of pulse methylprednisolone <i><i>versus<\/i><\/i> two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741-745.","DOI":"10.1016\/0140-6736(92)92292-N"},{"key":"ref-1555827","doi-asserted-by":"crossref","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D, et al. (2002): Immunosuppresive therapy in lupus nephritis (the Euro-Lupus Nephritis Trial, a randomized trial of low-dose <i><i>versus<\/i><\/i> high-dose intravenous cyclophosphamide). Arthritis  Rheum 46: 2121-2131.","DOI":"10.1002\/art.10461"},{"key":"ref-1555828","doi-asserted-by":"crossref","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D, et al. (2010): The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69: 61-64.","DOI":"10.1136\/ard.2008.102533"},{"key":"ref-1555829","doi-asserted-by":"crossref","unstructured":"Illei GG, Austin HA 3rd, Crane M, et al. (2001): Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135: 248-257.","DOI":"10.7326\/0003-4819-135-4-200108210-00009"},{"key":"ref-1555830","doi-asserted-by":"crossref","unstructured":"Grootscholten C, Ligtenberg G, Hagen EC, et al. (2006): Aza\u00adthio\u00adprine\/methylprednisolone <i><i>versus<\/i><\/i> cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 70: 732-742.","DOI":"10.1038\/sj.ki.5001630"},{"key":"ref-1555831","doi-asserted-by":"crossref","unstructured":"Arends S, Grootscholten C, Derksen RH, et al. (2012): Long-term follow-up of a randomised controlled trial of azathioprine\/methylprednisolone <i><i>versus<\/i><\/i> cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis 71: 966-973.","DOI":"10.1136\/annrheumdis-2011-200384"},{"key":"ref-1555832","doi-asserted-by":"crossref","unstructured":"Dooley MA, Jayne D, Ginzler EM, et al. (2011): Mycophenolate <i><i>versus<\/i><\/i> azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365: 1886-1895.","DOI":"10.1056\/NEJMoa1014460"},{"key":"ref-1555833","doi-asserted-by":"crossref","unstructured":"Appel GB, Contreras G, Dooley MA, et al. (2009): Mycophenolate mofetil <i><i>versus<\/i><\/i> cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20: 1103-1112.","DOI":"10.1681\/ASN.2008101028"},{"key":"ref-1555834","doi-asserted-by":"crossref","unstructured":"Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. (2010): Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 77: 152-160.","DOI":"10.1038\/ki.2009.412"},{"key":"ref-1555835","doi-asserted-by":"crossref","unstructured":"Austin HA 3rd, Illei GG, Braun MJ, et al. (2009): Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 20: 901-911.","DOI":"10.1681\/ASN.2008060665"},{"key":"ref-1555836","doi-asserted-by":"crossref","unstructured":"D\u00edaz-Lagares C, Croca S, Sangle S, et al. (2012) : Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 11: 357-364.","DOI":"10.1016\/j.autrev.2011.10.009"},{"key":"ref-1555837","doi-asserted-by":"crossref","unstructured":"J\u00f3nsd\u00f3ttir T, Gunnarsson I, Mour\u0103o AF, et al. (2010): Clinical improvements in proliferative <i>vs<\/i> membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology 49: 1502-1504.","DOI":"10.1093\/rheumatology\/keq055"},{"key":"ref-1555838","doi-asserted-by":"crossref","unstructured":"Rovin BH, Parikh SV (2014): Lupus nephritis: the evolving role of novel therapeutics. Am J Kidney Dis 63: 677-690.","DOI":"10.1053\/j.ajkd.2013.11.023"},{"key":"ref-1555839","doi-asserted-by":"crossref","unstructured":"Isenberg DA, Rahman A (2014): Taking a closer look at biologic therapy for SLE. Nat Rev Rheumatol 10: 71-72.","DOI":"10.1038\/nrrheum.2013.203"},{"key":"ref-1555840","doi-asserted-by":"crossref","unstructured":"Dooley MA, Houssiau F, Aranow C, et al. (2013): Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22: 63-72.","DOI":"10.1177\/0961203312465781"},{"key":"ref-1555841","doi-asserted-by":"crossref","unstructured":"Alarc\u00f3n GS, McGwin G, Bertoli AM, et al. (2007): LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from.","DOI":"10.1136\/ard.2006.068676"},{"key":"ref-1555842","unstructured":"LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66: 1168-1172."}],"container-title":["Central European Journal of Immunology"],"original-title":[],"link":[{"URL":"https:\/\/ceji.termedia.pl\/pdf-63700-130033","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ceji.termedia.pl\/pdf-63700-130033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:47:34Z","timestamp":1767948454000},"score":1,"resource":{"primary":{"URL":"https:\/\/ceji.termedia.pl\/Lupus-nephritis-in-children-10-years-experience,63700,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,25]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"alternative-id":["63700"],"URL":"https:\/\/doi.org\/10.5114\/ceji.2016.63123","relation":{},"ISSN":["1426-3912","1644-4124"],"issn-type":[{"value":"1426-3912","type":"print"},{"value":"1644-4124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,25]]}}}